Zydus Cadila Launches Ujvira (biosimilar- trastuzumab emtansine) for Early and Advanced HER2 Positive Breast Cancer
Shots:
- Ujvira is made by combining Trastuzumab and a cytotoxic compound Emtansine (DM1) utilizing a stable linker by Antibody Drug Conjugation and is supported by drug development program
- Ujvira be available in 2 strengths (100 & 60mg) and the therapy will be priced at nearly 80% less than the currently available option in the market (Rs. 1-59-225 for 100 mg vial)
- Patients already treated with Trastuzumab may still suffer with the disease and would require this therapy as the next step. The expensiveness is a barrier to availing this therapy and Ujvira will resolve this need
Ref: Zydus Cadila | Image: Dalal Street Investment Journa
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com